- Home
- GDEV vs TNGX Comparison
GDEV vs TNGX Comparison
Compare GDEV & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- TNGX
- Stock Information
- Founded
- GDEV 2009
- TNGX 2014
- Country
- GDEV Cyprus
- TNGX United States
- Employees
- GDEV N/A
- TNGX N/A
- Industry
- GDEV EDP Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- TNGX Health Care
- Exchange
- GDEV Nasdaq
- TNGX Nasdaq
- Market Cap
- GDEV 282.9M
- TNGX 317.4M
- IPO Year
- GDEV N/A
- TNGX N/A
- Fundamental
- Price
- GDEV $20.90
- TNGX $2.36
- Analyst Decision
- GDEV Buy
- TNGX Strong Buy
- Analyst Count
- GDEV 2
- TNGX 8
- Target Price
- GDEV $70.00
- TNGX $13.14
- AVG Volume (30 Days)
- GDEV 20.7K
- TNGX 574.3K
- Earning Date
- GDEV 03-18-2025
- TNGX 03-17-2025
- Dividend Yield
- GDEV N/A
- TNGX N/A
- EPS Growth
- GDEV N/A
- TNGX N/A
- EPS
- GDEV 2.04
- TNGX N/A
- Revenue
- GDEV $432,534,000.00
- TNGX $43,383,000.00
- Revenue This Year
- GDEV N/A
- TNGX $27.73
- Revenue Next Year
- GDEV $9.01
- TNGX N/A
- P/E Ratio
- GDEV $10.24
- TNGX N/A
- Revenue Growth
- GDEV N/A
- TNGX 15.67
- 52 Week Low
- GDEV $14.26
- TNGX $2.35
- 52 Week High
- GDEV $42.76
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- GDEV 67.29
- TNGX 33.13
- Support Level
- GDEV $14.26
- TNGX $2.35
- Resistance Level
- GDEV $15.80
- TNGX $2.51
- Average True Range (ATR)
- GDEV 1.17
- TNGX 0.22
- MACD
- GDEV 0.50
- TNGX -0.04
- Stochastic Oscillator
- GDEV 63.03
- TNGX 0.94
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.